biomea FUSION

COVALENT-101

Now recruiting

NCT05153330: Phase I Study of BMF-219, an oral covalent menin inhibitor, in patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)



Accelerated titration design followed by classical 3+3

Study Treatment

BMF-219

BMF-219, a covalent small molecule menin inhibitor, administered orally daily in 28-day cycles

Objectives

Primary

Determine OBD & RP2D of BMF-219 monotherapy independently for each Cohort and Arm

Secondary

- Evaluate safety and tolerability of BMF-219
- Determine PK/ PD parameters of BMF-219
- Explore additional evidence of efficacy and antitumor activity

Key Eligibility

- Age 18+
- ECOG score of ≤ 2, life expectancy ≥ 3 months
- Adequate organ function with prior treatment-related toxicities resolved to ≤ Grade 2
- Histologically or pathologically confirmed diagnosis of their malignancy
- Prior systemic therapy: ≥1L AL, ≥2L DLBCL & CLL, ≥3L MM
- Additional eligibility criteria apply.

Abbreviations: ALL Acute Lymphoblastic Leukemia **AML** Acute Myeloid Leukemia **AMPL** Acute Mixed-Phenotype Leukemia **CYP3A4** Cytochrome 450 **OBD** Optimal biologic dose **DLBCL** diffuse large B-cell lymphoma **MM** multiple myeloma **CLL** chronic lymphocytic leukemia **R/R** Relapsed/Refractory **RP2D** recommended phase 2 dose **PK/PD** pharmacokinetic/pharmacodynamic **ECOG** Eastern Cooperative Oncology Group **var** variable **L** prior line of systemic therapy

biomea FUSION™

We Aim to Cure™

Biomea Fusion, Inc.
900 Middlefield Road, 4th floor
Redwood City, CA 94063
1 (650) 980-9099
biomeafusion.com

COVALENT-101